BioWorld Asia

May 18, 2005

NovImmune, Serono Enter Antibody Deal Worth $122M

NovImmune SA entered its first product out-licensing pact, a deal with Serono SA, which is potentially worth up to $122 million for two preclinical fully human antibodies, NI-0401 and NI-0501. (BioWorld International) Read More

To Increase Pipeline, CAT Pushing Back Profitability

Positive Results At ASCO For Nicotine Vaccine Raise Hopes

AC Immune Gets CHF21M For Sensitive Antibodie

Initiatives Aim To Make UK Top Spot For Clinical Trials

Intec Pharma Gets New CEO, Plans 'Accordion Pill' Program

Law On Agricultural Biotech Stuck In German Parliament

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...